Mohamed Morsy, MD
Interventional Cardiology · Memphis, TNNPI 1851670608
Payments from drug & device makers
Across 195 payments — averaging $101.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Penumbra, Inc.$4K
- Abbott$2K
- Boston Scientific$1K
- Shockwave Medical, Inc$547
- Inari Medical, Inc.$499
- plus $4K from 27 others
What the payments were for
- Travel & lodging$10,75455%
- Food & beverage$8,79245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $8,190 |
| Penumbra, Inc. | 15 | $3,587 |
| Abbott | 20 | $2,263 |
| Boston Scientific | 21 | $1,010 |
| Shockwave Medical, Inc | 9 | $547 |
| Inari Medical, Inc. | 5 | $499 |
| Asahi Intecc USA, Inc. | 5 | $450 |
| Siemens Medical Solutions USA, Inc. | 4 | $355 |
| Biotronik Inc. | 3 | $325 |
| Philips North America LLC | 10 | $316 |
| Amgen | 5 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $243 |
| Novo Nordisk | 7 | $234 |
| EKOS Corporation | 2 | $215 |
| Edwards Lifesciences | 2 | $179 |
| Bard Peripheral Vascular, Inc. | 2 | $132 |
| Cardiovascular Systems Inc. | 7 | $115 |
| Akcea Therapeutics, Inc. | 1 | $106 |
| Pfizer | 6 | $101 |
| Nuwellis, Inc. | 2 | $95 |
| Novartis | 6 | $88 |
| Abiomed | 1 | $83 |
| Biocompatibles, Inc. | 1 | $82 |
| W. L. Gore & Associates, Inc. | 3 | $49 |
| AstraZeneca | 3 | $41 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Cvrx, Inc. | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Agepha Pharma FZ LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$6,403
- Indigo$2,616
- Indigo System$1,866
- OPTIS$1,294
- RESOLUTE ONYX$954
- FLOWTRIEVER CATHETER, S$481
- ASAHI PTCA Guide Wire$395
- Vascular Lithotripsy$258
- Acticor 7 VR-T DX$227
- GENERAL - STRUCTURAL HEART$225
- EKOSONIC$215
- SAPIEN 3 Ultra RESILIA$172
- MitraClip$150
- GENERAL - THERAPIES$148
- COROFLOW$146
- CardioMEMS HF System$141
- CT THROMBECTOMY SYSTEM KIT$133
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$129
- Rotablator Rotational Atherectomy System Console Kit$127
- Wegovy$125
How this compares
$19,741 in reported general payments places this provider in the 70th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $397,923 |
| JardianceEmpagliflozin | 104 | $132,934 |
| Repatha SureclickEvolocumab | 65 | $85,275 |
| XareltoRivaroxaban | 45 | $63,458 |
| EntrestoSacubitril/Valsartan | 41 | $62,994 |
| FarxigaDapagliflozin Propanediol | 29 | $33,495 |
| Repatha SyringeEvolocumab | 22 | $25,150 |
| BrilintaTicagrelor | 12 | $9,115 |
| Metoprolol Succinate | 666 | $8,257 |
| Rosuvastatin Calcium | 528 | $7,231 |
| Ezetimibe | 155 | $3,447 |
| ClopidogrelClopidogrel Bisulfate | 268 | $3,191 |
| Spironolactone | 381 | $2,982 |
| Valsartan | 126 | $2,623 |
| Losartan Potassium | 264 | $2,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $101 | $397,923332 claims |
| NovartisEntresto | $88 | $62,99441 claims |
| AstraZenecaFarxiga, Brilinta | $41 | $42,61041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Memphis
- Joseph WeinsteinMemphis$653K
- Claro DiazMemphis$184K
- Dwight DishmonMemphis$139K
- Benjamin WallerMemphis$53K
- Stevan HimmelsteinMemphis$25K
- Michael MorseNashville$3.5M
- Charles TreasurePowell$3M
- Colin BarkerNashville$2.1M
- Brian JeffersonNashville$2.1M
- Malcolm FosterKnoxville$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.